IT IS PROPOSED THAT AN EYE DROP DELIVERY SYSTEM WHOSE DESIRED FEATURES HAVE BEEN DEMONSTRATED BY AN OPERATIONAL MODEL BE DEVELOPED INTO A PRODUCTION PROTOTYPE THAT CAN BE MANUFACTURED AS A FINISHED PRODUCT, EXCLUSIVE OF CONTENTS, FOR A COST OF LESS THAN

IT IS PROPOSED THAT AN EYE DROP DELIVERY SYSTEM WHOSE DESIRED FEATURES HAVE BEEN DEMONSTRATED BY AN OPERATIONAL MODEL BE DEVELOPED INTO A PRODUCTION PROTOTYPE THAT CAN BE MANUFACTURED AS A FINISHED PRODUCT, EXCLUSIVE OF CONTENTS, FOR A COST OF LESS THAN $1. THE DEVICE WILL DELIVER WITHOUT REQUIRING UNUSUAL HEAD POSTURING OR EYELID MANIPULATION PRECISE MICRO- AMOUNTS OF MEDICATION DIRECTLY TO THE CORNEA. IT WILL REQUIRE MINIMAL PATIENT DEXTERITY. THE DEVICE WILL BE DISPOSABLE, NON-REFILLABLE, AND MAINTAIN ITS CONTENTS STERILE. LESS QUANTITY OF ACTIVE INGREDIENTS SHOULD BE REQUIRED TO PROVIDE THE DESIRED THERAPEUTIC EFFECT, AND NON-PRESERVED AGENTS SHOULD MAINTAIN THEIR STERILITY, THUS PROVIDING THE OPPORTUNITY TO REDUCED SIDE EFFECTS PRODUCED BY OVER MEDICATION OR PRESERVATIVES INHERENT IN PRESENT DROP DELIVERY SYSTEMS.